Winton Group’s Aerie Pharmaceuticals AERI Stock Holding History

Winton Group’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,533	Closed	-$464K	–	1083
2018 Q3	$464K	Sell	7,533 -556	-7%	-$35.7K	0.01%	656
2018 Q2	$546K	Sell	8,089 -9,283	-53%	-$519K	0.01%	614
2018 Q1	$942K	Buy	+17,372	New	+$972K	0.03%	526

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Winton Group's AERI Position: Q4 2018 in Review

Winton Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 7,533 shares — an estimated $464K sold.

Winton Group first reported a position in AERI in Q1 2018 and held it in 3 quarters. The position peaked at $942K in Q1 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Winton Group reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Winton Group sold 7,533 Aerie Pharmaceuticals shares in Q4 2018, an estimated $464K.
Winton Group first reported a position in Aerie Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Winton Group's Aerie Pharmaceuticals position peaked at $942K in Q1 2018.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Winton Group's 13F filing for Q4 2018, filed 5 Feb 2019.